Mr. Handrinos is described as "one of the best life sciences lawyers in Boston." Legal 500 USA

Peter N. Handrinos

Boston | New York
  • John Hancock Tower, 27th Floor
  • 200 Clarendon Street
  • Boston, MA 02116
  • USA
 
 

Peter Handrinos practices corporate and securities law, with an emphasis on mergers and acquisitions, capital markets and venture capital transactions for life sciences and technology companies. Mr. Handrinos advises both public and private companies in connection with a broad range of matters, including:

  • IPOs
  • Follow-on offerings
  • Strategic investments
  • 144A offerings
  • Cash and stock mergers
  • Tender offers
  • Going-private transactions

He counsels numerous start-up companies and venture capital firms in venture capital financings. Mr. Handrinos also regularly represents investment banks in connection with capital markets transactions. A significant portion of his practice involves general corporate work for ongoing clients on matters such as SEC compliance, securities and disclosure issues, and corporate governance matters.

The Legal 500 USA described Mr, Handrinos as “one of the best life sciences lawyers in Boston.” He has been recognized as a leader in Corporate/M&A by Chambers USA since 2007, where he is also described as a “superb attorney – exceptionally bright, attentive to details and remarkably hard working.” He has been listed in the 2012 through 2014 editions of Best Lawyers in America as a leader in mergers and acquisitions.

Mr. Handrinos's representative transactions includes advising:

  • T2 Biosystems in its US$65.8 million IPO
  • Epirus Biopharmaceuticals in its merger with Zalicus
  • Morgan Stanley and BAML in US$100.7 million offering by Sarepta Therapeutics
  • Radius Health in its US$52 million IPO
  • RBC Capital and William Blair in US$55 million IPO by Agile Therapeutics
  • Morgan Stanley and Credit Suisse in US$115 million IPO by Akebia Therapeutics

  • Aratana Therapeutics in its: 
    • US$97.9 million follow-on offering 
    • €33.3 million acquisition of Okapi Sciences BV 
    • US$30 million acquisition of Vet Therapeutics Inc. 
    • US$19.8 million PIPE financing
    • US$39.7 million IPO
  • BIND Therapeutics in its US$70.5 million IPO
  • Barclays and Jefferies in its US$64.8 million IPO by Trevena
  • Stifel and BMO in US$96.6 million IPO by Auspex Pharmaceuticals
  • Stifel and Piper Jaffray in US$63.3 million IPO offering by Cara Therapeutics
  • BMO and Stifel in US$45 million follow-on offering by Tetraphase Pharmaceuticals
  • Barclays and BMO in US$75 million IPO by Tetraphase Pharmaceuticals
  • Barclays Capital in its US$49.6 million US IPO by Mazor Robotics
  • A123 Systems in US$254 million concurrent common stock and convertible subordinated notes offerings
  • American Superconductor in its terminated US$265 million proposed acquisition of The Switch
  • American Superconductor in US$25 million convertible note and warrant financing
  • Chiasma in its US$595 milllion collaboration with Roche
  • J.P. Morgan, Cowen and Jefferies in US$258 million follow-on offering by ARIAD Pharmaceuticals
  • J.P. Morgan in its US$50.2 million follow-on offering by ZIOPHARM Oncology
  • Morgan Stanley and Jefferies in US$100 million follow-on offering by Immunogen
  • Morgan Stanley, Barclays and Goldman Sachs in US$569 IPO by Sensata Technologies Holding N.V.
  • MPM Capital in connection with the financing and collaboration between Astellas and Mitokyne
  • MPM Capital in connection with the financing and collaboration between Novartis and Sideris
  • MPM Capital and Kaiser Permanente Ventures in US$40.4 million Series C financing for Astute Medical
  • Selecta Biosciences in a US$47.25 million financing